Celebrity-backed cancer drug firm Ellipses Pharma targets London float
Ellipses Pharma targets London listing with celebrity backers

Ellipses Pharma, a clinical-stage oncology company backed by celebrity investors and Middle Eastern sovereign wealth, is preparing to float on the London Stock Exchange. The company, founded by prominent British biotech entrepreneur Sir Chris Evans, is planning to reverse into a newly formed entity, with reports in The Times suggesting a target listing valuation of between £450m and £500m.

Backers and Shareholding

Among the company's backers are Evans himself, Redrow housebuilder founder Steve Morgan, and Scottish entrepreneur Sir Tom Hunter's investment vehicle West Coast Capital. A number of high-profile celebrity investors have also lent their support, including comedian Jimmy Carr and Andrew Lloyd Webber.

The venture's single largest shareholder is Abu Dhabi's sovereign wealth fund, which holds a 45 per cent stake. Waleed al-Mokarrab al-Muhairi, deputy chief executive of Mubadala Investment Company, sat on the firm's board until March 2025, as reported by City AM. The company launched a clinical trial programme in the UAE in December 2024.

Listing Plans and Advisers

Evans, who has overseen the founding and flotation of numerous biotech firms including Enzymatix and Celsis, had previously been weighing up a listing outside of London. The entrepreneur had been considering the Nasdaq as Ellipses' potential home, while Hong Kong was also mooted as a possible venue in 2025.

However, Ellipses is now eyeing a London listing as early as February via a reverse takeover of Wolfram Resources, a cash shell previously focused on precious metals exploration investment across central Asia. Private bank Berenberg is reported to have been appointed to oversee the deal, while Ellipses is also preparing to bring non-executive directors onto its board ahead of a listing.

Royal Bank of Canada and Pharma Ventures, an M&A advisory firm, are understood to have been lined up to advise on potential out-licensing agreements with major pharmaceutical companies. A formal announcement could come as early as this week.

Impact on London's Biotech Sector

Reverse takeovers offer a swifter route to raising capital on public markets compared to a traditional initial public offering, and the Nasdaq has been inundated with such deals throughout the course of this year. A successful listing would also deliver London a much-needed boost, as the capital continues to absorb the impact of a wave of delistings alongside a persistent drain of IPOs.

Most notably, it would bolster London's biotech and pharmaceutical sector, which has witnessed companies increasingly casting their eyes towards America. FTSE heavyweight AstraZeneca has shifted its focus closer to the US over the past year, enhancing its listing on the New York Stock Exchange.

Ellipses employs around 40 people, drawn predominantly from major pharmaceutical firms, and has invested roughly £185m in its drug pipeline.